[Federal Register Volume 59, Number 72 (Thursday, April 14, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-8975]


[[Page Unknown]]

[Federal Register: April 14, 1994]


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES
 

Prospective Grant of Exclusive License: Treatment of Dopaminergic 
Neurodegenerative Disorders

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive world-wide license to practice the invention embodied in 
U.S. Patent Applications SN 07/401,141 and 07/892,485, both entitled 
``A Method for the Treatment of Dopaminergic Neurodegenerative 
Disorders'' to Phoenix: Regenerative Technologies, Inc. of Peoria, 
Illinois. The patent rights in this invention have been assigned to the 
United States of America.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
This prospective exclusive license may be granted unless within 60 days 
from the date of this published notice, NIH receives written evidence 
and argument that establishes that the grant of the license would not 
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    The patent applications disclose a novel surgical implantation 
method, which comprises implantation, into the brain, of suitable 
histocompatible leukocytes activates by such agents as plant mitogens, 
lymphokines, and cytokines. The claimed process offers an improved 
method of treating Parkinson's disease and other diseases that affect 
the dopaminergic system. This therapy can reduce or totally eliminate 
L-Dopa therapy, which has significant toxic side effects, and also 
presents an alternative to fetal implantation therapy. Use of the 
patient's own autologous leukocytes is also convenient and reduces the 
chance of host rejection.

ADDRESSES: Requests for a copy of this patent application, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Mr. Arthur J. Cohn, J.D., Technology Licensing 
Specialist, Office of Technology Transfer, National Institutes of 
Health, Box OTT, Bethesda, MD 20892. Telephone: (301) 496-7735; 
Facsimile: (301) 402-0220. A signed Confidentiality Agreement will be 
required to receive a copy of the patent application. Applications for 
a license in the indicated exclusive fields filed in response to this 
notice will be treated as objections to the grant of the contemplated 
license. Only written comments and/or applications for a license which 
are received by NIH within sixty (60) days of this notice will be 
considered.

    Dated: March 31, 1994.
Donald P. Christoferson,
Acting Director, Office of Technology Transfer.
[FR Doc. 94-8975 Filed 4-13-94; 8:45 am]
BILLING CODE 4140-01-M